🔗 Share this article

The initial novel therapies for gonorrhoea in many years are being hailed as a "huge turning point" in the battle against superbug strains of the pathogen, according to health experts.

A Global Challenge

Gonorrhoea infections are increasing around the world, with data suggesting over 82 million instances per year. Particularly high rates are reported in Africa and countries within the WHO's designated area, which includes China and Mongolia to New Zealand. Across England, cases have hit a record high, while figures across Europe in 2023 were triple the level compared to those in 2014.

“The clearance of new treatments for gonorrhoea is an important and timely step in the face of increasing worldwide cases, increasing antimicrobial resistance and the very limited treatment choices currently available.”

Public health authorities are increasingly worried about the increase in drug-resistant strains. The WHO has listed it as a "high-priority threat". Ongoing monitoring showed that resistance to key first-line drugs like ceftriaxone and cefixime jumped significantly between 2022 and 2024.

Two New Therapies Gain Approval

One new antibiotic, alternatively called a brand name, was authorized by the US Food and Drug Administration in mid-December for use against gonorrhoea. This disease can lead to significant complications, including the inability to conceive. Researchers hope that targeted use of this new drug will help slow the spread of drug resistance.

Gepotidacin, originating from the pharmaceutical company GlaxoSmithKline, also received approval in the same week. This treatment, which is also used to treat urinary tract infections, was proven in research to be able to combat drug-resistant strains of the gonorrhoea bacteria.

A Novel Development Model

This new treatment emerged from a new, not-for-profit approach for medication research. The non-profit organisation GARDP collaborated with the pharmaceutical company Innoviva to bring it to fruition.

“This approval marks a significant shift in the treatment of highly resistant gonorrhoea, which previously has been evolving faster than antibiotic development.”

Research Study Outcomes and Global Access

According to results detailed in a major medical journal, the new drug successfully treated more than 90% of cases of the STI. This establishes an similar efficacy with the typical regimen, which combines a dual-drug approach. The trial involved over 900 participants from various regions including the United States, Thailand, South Africa, and European nations.

As part of the agreement of its development partnership, GARDP has the ability to license and sell the drug in numerous developing nations.

Clinicians directly involved have expressed positive views. Access to a one-pill regimen of this kind is hailed as a "revolutionary step" for managing the epidemic. This is deemed essential to alleviate the strain of the infection for individuals and to prevent the spread of untreatable gonorrhoea worldwide.